Our vision is to free diabetics from the painful finger prick and throughout this leverage for our shareholders the significant market potential that such a non-invasive glucose monitor could achieve.
Diabetes is a global problem; almost 600m patients will be suffering from this disease by 2032. The majority of severe diabetics undergo a painful reminder of their disease multiple times a day by means of drawing blood to measure their glucose levels. I strongly believe that we can free the diabetic from this antiquated and painful reminder, which is why NovioSense set out in 2012 to reinvent the way we measure glucose. We believe that by reimagining the finger strip technology into a new form factor our non-invasive device will allow patients to monitor glucose levels on demand not only non-invasively but also unobtrusively. We have discovered that tears are a unique source of biomarkers with excellent prediction of blood biomarker levels. Armed with this knowledge we have developed a non-invasive sensor capable of detecting trace levels of glucose in tears and accurately extrapolating these values back to blood glucose levels.
It is our vision that this technology will be a user-friendly replacement for the painful finger prick. We have designed our device from the ground up to replace the finger prick. The detection method employs the same robust enzymatic detection used in current state of the art glucose monitors. The small form factor of the sensor makes it easy to place and remove behind the lower eyelid without specialist training. Smart hydrogel coatings sourced from sustainable sources create a soft interface between the eye and the sensor facilitating extended wear times. The combination of these features will enable us to develop a continuous glucose monitor that breaks free of the niche market and presents a real challenge to the finger prick. This means that in the time ahead we will work passionately as a team to realize this revolutionary technique and to ensure that it is ready to enter the market in 2018.